X

Vous n'êtes pas connecté

Maroc Maroc - PHARMABIZ.COM - A la Une - 13/Aug 00:00

scPharmaceuticals announces positive results from pharmacokinetic study of SCP─111 autoinjector

scPharmaceuticals Inc., a pharmaceutical company, announced positive topline results from the pharmacokinetic (PK) study of SCP─111, an investigational, low volume, pH neutral formulation of furosemide

Articles similaires

Sorry! Image not available at this time

Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma

pharmabiz.com - 14/Sep 23:19

Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...

Sorry! Image not available at this time

Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)

drugs.com - 05/Sep 05:09

BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...

Sorry! Image not available at this time

Crestone Announces Positive Data From Phase 2 Clinical Trial of CRS3123 for C. Difficile Infections (CDI)

drugs.com - 05/Sep 05:09

BOULDER, Colo.--(BUSINESS WIRE)-- September 05, 2024 -- Crestone, Inc. (“Crestone”) today announced positive topline results from the Phase 2...

Sorry! Image not available at this time

In a First-of-its-kind Fixed Dose Study, Once Weekly Insulin Efsitora Alfa Leads to A1C Reduction Similar to Daily Insulin

drugs.com - 05/Sep 06:09

INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...

Sorry! Image not available at this time

In a First-of-its-kind Fixed Dose Study, Once Weekly Insulin Efsitora Alfa Leads to A1C Reduction Similar to Daily Insulin

drugs.com - 05/Sep 06:09

INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...

Sorry! Image not available at this time

Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome

pharmabiz.com - 04/Sep 00:00

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Sorry! Image not available at this time

Regenxbio reports positive results from phase I/II/III CAMPSIITE trial of RGX─121 to treat patients with Hunter syndrome

pharmabiz.com - 04/Sep 00:00

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Sorry! Image not available at this time

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

zacks.com - 04/Sep 14:34

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Sorry! Image not available at this time

Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures

zacks.com - 04/Sep 14:34

Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.

Les derniers communiqués

  • Aucun élément